ArticleJournal of hepatocellular carcinoma2026
Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The combination of transarterial chemoembolization (TACE), lenvatinib and PD-1 inhibitors (triple therapy) demonstrates encouraging efficacy in patients with unresectable hepatocellular carcinoma (uHCC). But its prognostic value remains unclear in patients with double negative des gamma carboxy prothrombin (DCP) and alpha fetoprotein (AFP) uHCC. To identify the best candidates for this treatment, this study aimed to evaluate the prognosis of this specific population and to establish a practical prognostic scoring model. Methods: This multicenter retrospective study included 136 patients with double-negative DCP/AFP uHCC receiving triple therapy, stratified into training (n=91) and validation (n=45) cohorts. Independent predictors for overall survival (OS) were identified by Cox regression to build a scoring system. The model's performance was validated using Kaplan-Meier curves and the area under the receiver operating characteristic curve (AUC). Results: In the training cohort, median OS was not reached, and median progression-free survival was 18.9 months. Additionally, triple therapy produced a 79.1% objective response rate and a 95.6% disease control rate. Four variables (maximal tumor size ≥ 5 cm, absence of conversion surgery, presence of extrahepatic metastasis, and age < 55 years), were independent risk factors for prognosis and were utilized to develop the SEA score. The SEA score effectively stratified patients into low risk (0-3 points) and high risk (4-6 points) groups, with significantly different survival outcomes in both cohorts. This model showed robust discriminative performance, with AUCs of 0.80 in the training cohort and 0.68 in the validation cohort, and outperformed all individual prognostic factors. Conclusion: Triple therapy demonstrates promising efficacy and an acceptable safety profile in patients with double-negative DCP/AFP uHCC. The SEA score effectively stratifies patient outcomes, facilitating the identification of optimal candidates for triple therapy, though prospective validation is warranted before widespread clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.